Accéder au contenu
Merck
  • A model for evaluating topical antimicrobial efficacy against methicillin-resistant Staphylococcus aureus biofilms in superficial murine wounds.

A model for evaluating topical antimicrobial efficacy against methicillin-resistant Staphylococcus aureus biofilms in superficial murine wounds.

Antimicrobial agents and chemotherapy (2012-05-31)
Eric D Roche, Paul J Renick, Shannon P Tetens, Dennis L Carson
RÉSUMÉ

A wound biofilm model was created by adapting a superficial infection model. Partial-thickness murine wounds were inoculated with methicillin-resistant Staphylococcus aureus (MRSA). Dense biofilm communities developed at the wound surface after 24 h as demonstrated by microscopy and quantitative microbiology. Common topical antimicrobial agents had reduced efficacy when treatment was initiated 24 h after inoculation compared to 4 h after inoculation. This model provides a rapid in vivo test for new agents to treat wound biofilm infections.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Bacitracine, from Bacillus licheniformis, ≥65 IU/mg
Sigma-Aldrich
Bacitracine, from Bacillus licheniformis, ≥65 IU/mg
Sigma-Aldrich
Silver(I) sulfadiazine, 98%
Sigma-Aldrich
Bacitracin zinc salt, from Bacillus licheniformis, ~70,000 U/g